Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Claire Bonfils"'
Autor:
Zuomei Li, Jeffrey M. Besterman, A. Robert MacLeod, Daniel Delorme, Oscar Moradei, Sylvain Lefebvre, Jubrail Rahil, Hélène Ste-Croix, James J. Wang, Jeffrey Gillespie, Marie-France Robert, Nancy Z. Zhou, Ai-Hua Lu, Jianhong Liu, Ann Kalita, Marie-Claude Trachy-Bourget, Pu Theresa Yan, Yu Hou, Claire Bonfils, Marielle Fournel
Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37be0158a4c3ff3f1783a4ed1271cd1d
https://doi.org/10.1158/1535-7163.c.6531123.v1
https://doi.org/10.1158/1535-7163.c.6531123.v1
Autor:
Zuomei Li, Jeffrey M. Besterman, A. Robert MacLeod, Daniel Delorme, Oscar Moradei, Sylvain Lefebvre, Jubrail Rahil, Hélène Ste-Croix, James J. Wang, Jeffrey Gillespie, Marie-France Robert, Nancy Z. Zhou, Ai-Hua Lu, Jianhong Liu, Ann Kalita, Marie-Claude Trachy-Bourget, Pu Theresa Yan, Yu Hou, Claire Bonfils, Marielle Fournel
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489f53ab3050b1c461753e8c3470afee
https://doi.org/10.1158/1535-7163.22483368
https://doi.org/10.1158/1535-7163.22483368
Autor:
Zuomei Li, Jeffrey M. Besterman, A. Robert MacLeod, Daniel Delorme, Oscar Moradei, Sylvain Lefebvre, Jubrail Rahil, Hélène Ste-Croix, James J. Wang, Jeffrey Gillespie, Marie-France Robert, Nancy Z. Zhou, Ai-Hua Lu, Jianhong Liu, Ann Kalita, Marie-Claude Trachy-Bourget, Pu Theresa Yan, Yu Hou, Claire Bonfils, Marielle Fournel
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dfa14777fa57c3391ea3a30617e6ac2
https://doi.org/10.1158/1535-7163.22483365.v1
https://doi.org/10.1158/1535-7163.22483365.v1
Autor:
Israel Matos, Yahya Ashraf, Hiba Zahreddine, Liying Gong, Amanda Baumholtz, Alex Zhou, Claire Bonfils, Aniel Moya-Torres, Yun Cui, Xiaowei Wang, Richard Wargachuk, Tiffany Cheng, Elijus Undzys, Shugang Yao, Jacynthe Linda Tolouse, Dominic Hou, Gordon Ngan, Luis daCruz, David Young
Publikováno v:
Cancer Research. 82:324-324
Trophoblast cell surface antigen-2 (TROP2) is a membrane-bound protein expressed during development and at lower levels in normal adult tissues. TROP2 has pleiotropic functions including formation of cell-cell junctions by mediating interactions with
Autor:
Shugang Yao, Yun Cui, Anna Kazanats, Liying Gong, Claire Bonfils, Dominic Hou, Emily Chen, Elijus Undzys, Jacynthe Toulouse, Milica Krstic, Hiba Zahreddine, Israel Matos, Alex Zhou, Aniel Moya-Torres, Richard Wargachuk, Carl Gay, Lauren Byers, Gordon Ngan, Luis da Cruz, David Young
Publikováno v:
Molecular Cancer Therapeutics. 20:P200-P200
We developed a single domain VHH multi-specific antibody format. Multispecific antibodies have multiple mechanisms of action which may work independently or together, to achieve better clinical outcomes in cancers with high unmet medical need such as
Autor:
Israel Matos, Hiba Zahreddine, Yahya Ashraf, Aditya Pandey, Emily Chen, Liying Gong, Alex Zhou, Claire Bonfils, Aniel Moya, Yun Cui, Xiaowei Wang, Elijus Undzyz, Shugang Yao, Jacynthe Toulouse, Dominic Hou, Gordon Ngan, Luis da Cruz, David Young
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA018-LBA018
Trophoblast cell surface antigen-2 (TROP2) is a membrane-bound protein with an extracellular domain highly expressed in a wide range of late-stage epithelial cancers. TROP2 upregulation in solid cancers is associated with increased tumor aggressivene
Autor:
Milica Krstic, Morin Nicolas, Jacynthe L. Toulouse, Shugang Yao, Dominic Hou, David Young, Claire Bonfils, Yun Cui, Luis A. G. Dacruz, Donald Gagné, Elijus Undzys, Ashwani K. Gupta, Emily I. Chen, Alex Zhou, Richard Wargachuk
Publikováno v:
Cancer Research. 81:LB094-LB094
Monoclonal antibody therapy has revolutionized cancer treatment by addressing a variety of mechanisms from interfering with signaling to checkpoint inhibition. Bispecific antibodies double the number of therapeutic mechanisms addressed by each antibo
Publikováno v:
Expert Opinion on Drug Discovery. 3:1041-1065
Background: Histone deacetylases (HDACs) constitute a family of enzymes that deacetylate histones and other cellular proteins. They are major regulators of transcription and are also important in other cellular processes. Objective: The review provid
Autor:
Wilson H. Miller, Marja Dubay, Tracy Patterson, Zeev Estrov, Zuomei Li, Caroline Rousseau, Eric Laille, Gregory K. Reid, Guillermo Garcia-Manero, Sarit Assouline, Robert E. Martell, Ann Kalita, Willie Newsome, Claire Bonfils, H. Yang, Hagop M. Kantarjian, Jorge E. Cortes, Mark D. Minden, J. M. Besterman
Publikováno v:
Blood. 112:981-989
MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without
Autor:
Ann Kalita, Pu Theresa Yan, Yu Hou, Marielle Fournel, Zuomei Li, Jubrail Rahil, Jeffrey M. Besterman, Jeffrey M. Gillespie, Marie-Claude Trachy-Bourget, Nancy Z. Zhou, Sylvain Lefebvre, Jianhong Liu, Oscar Moradei, Daniel Delorme, Hélène Ste-Croix, Marie-France Robert, James Wang, Aihua Lu, A. Robert MacLeod, Claire Bonfils
Publikováno v:
Molecular Cancer Therapeutics. 7:759-768
Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneo